Nicole M Iovine, MD, PhD
Program Director; Clinical Professor & Hospital Epidemiologist
Department:
MD-INFECTIOUS DISEASES
Business Phone:
(352) 273-8606
Business Email:
nicole.iovine@medicine.ufl.edu
About Nicole M Iovine
Additional Positions:
Section Chief, Epidemiology and Antimicrobial Stewardship
2018 – Current
·
University of Florida
Accomplishments
Fellow of the Infectious Disease Society of America
2017
·
Infectious Disease Society of America
Outstanding Leadership in Quality and Patient Safety
2014
·
University of Florida Health
Excellence in Teaching Award
2012
·
University of Florida
Special Citation of Excellence for a Poster Presentation
2005
·
43rd Annual Meeting of the IDSA
Infectious Disease Fellow of the Year
2002
·
New York University
Alpha Omega Alpha Honor Society
2000
·
New York University School of Medicine
Golden Key National Honor Society
1992
·
City University of New York
Valedictorian
1992
·
City University of New York
Teaching Profile
Courses Taught
2018
MDT7200 Elect Top/Medicine
2018
BMS6300 Fund Micro and Immuno
Board Certifications
-
Infectious DiseaseAmerican Board of Internal Medicine
-
Internal MedicineAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Infectious Disease
Areas of Interest
- Avian influenza
- Coronavirus disease 2019 (COVID-19)
- Infectious diseases
Research Profile
I am trained as both an Infectious Disease specialist and as an expert in innate defense against bacterial infection, with a focus on Gram-negative organisms. As an Infectious Disease specialist, I am particularly interested in treatment approaches to multidrug-resistant Gram-negative infections. As a researcher, I study the innate defenses against these types of infections. In one project, I study the Bactericidal/Permeability-Increasing protein (BPI) – an endogenous antibiotic found in neutrophils and available in recombinant form. BPI has potent activity against Gram-negative bacteria, including multidrug-resistant clinical isolates I collect.
I have also studied emerging infections, such as chikungunya, Zika and seasonal influenza. I was engaged in two NIH-sponsored clinical trials for the treatment of seasonal influenza with immune plasma and triple therapy (ribivirin, oseltamivir and amantadine). I was the Principal Investigator for UF site of the NIH-sponsored Adaptive COVID-19 Treatment Trials (ACTT), which identified remdesivir and baricitinib as important agents for the treatment of COVID patients. Most recently, I am the Principal Investigator for the UF site of the STOMP monkeypox clinical trial, and for the Accelerating COVID-19 Therapeutic Interventions and Vaccines clinical trials (ACTIV4a and ACTIV4d).
Open Researcher and Contributor ID (ORCID)
0000-0002-5032-6485
Publications
2022
Association between lipid profiles and viral respiratory infections in human sputum samples.
Respiratory research.
23(1)
[DOI] 10.1186/s12931-022-02091-w.
[PMID] 35780155.
2022
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.
The Lancet. Respiratory medicine.
10(9):888-899
[DOI] 10.1016/S2213-2600(22)00088-1.
[PMID] 35617986.
2022
Isolation of a Novel Recombinant Canine Coronavirus From a Visitor to Haiti: Further Evidence of Transmission of Coronaviruses of Zoonotic Origin to Humans.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
75(1):e1184-e1187
[DOI] 10.1093/cid/ciab924.
[PMID] 34718467.
2021
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
The New England journal of medicine.
384(9):795-807
[DOI] 10.1056/NEJMoa2031994.
[PMID] 33306283.
2021
Disseminated genitourinary histoplasmosis in a patient with AIDS with negative urine antigen testing.
BMJ case reports.
14(11)
[DOI] 10.1136/bcr-2021-243375.
[PMID] 34772673.
2021
Dissemination mechanisms of NDM genes in hospitalized patients.
JAC-antimicrobial resistance.
3(1)
[DOI] 10.1093/jacamr/dlab032.
[PMID] 34223104.
2021
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.
The Lancet. Respiratory medicine.
9(12):1365-1376
[DOI] 10.1016/S2213-2600(21)00384-2.
[PMID] 34672949.
2020
Evaluation of patient risk factors for infection with carbapenem-resistant Enterobacteriaceae.
American journal of infection control.
48(9):1028-1031
[DOI] 10.1016/j.ajic.2019.11.025.
[PMID] 31924388.
2020
Optimizing COVID-19 testing capabilities and clinical management using pathology informatics.
JAMIA open.
3(4):523-529
[DOI] 10.1093/jamiaopen/ooaa055.
[PMID] 33754137.
2020
Recovery of Curvularia mold from a duodenoscope after reprocessing in accordance with the manufacturer’s cleaning protocol.
American journal of infection control.
48(1):119-121
[DOI] 10.1016/j.ajic.2019.06.025.
[PMID] 31439371.
2020
The Clinical Presentation and Immunology of Viral Pneumonia and Implications for Management of Coronavirus Disease 2019.
Critical care explorations.
2(4)
[DOI] 10.1097/CCE.0000000000000109.
[PMID] 32426751.
2018
IKBKG (NEMO) 5′ Untranslated Splice Mutations Lead to Severe, Chronic Disseminated Mycobacterial Infections.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
67(3):456-459
[DOI] 10.1093/cid/ciy186.
[PMID] 29534156.
2018
Infectious Diseases Physicians: Leading the Way in Antimicrobial Stewardship.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
66(7):995-1003
[DOI] 10.1093/cid/cix1093.
[PMID] 29444247.
2017
Complete Genome Sequence of Dengue virus Type 2 from a Resident of North-Central Florida with Locally Transmitted Dengue Fever.
Genome announcements.
5(31)
[DOI] 10.1128/genomeA.00782-17.
[PMID] 28774993.
2016
Hemagglutinin Gene Clade 3C.2a Influenza A(H3N2) Viruses, Alachua County, Florida, USA, 2014-15.
Emerging infectious diseases.
22(1):121-3
[DOI] 10.3201/2201.151019.
[PMID] 26692074.
2016
Zika and Chikungunya virus co-infection in a traveller returning from Colombia, 2016: virus isolation and genetic analysis.
JMM case reports.
3(6)
[DOI] 10.1099/jmmcr.0.005072.
[PMID] 28348794.
2015
An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA.
Clinical toxicology (Philadelphia, Pa.).
53(10):950-6
[DOI] 10.3109/15563650.2015.1100306.
[PMID] 26555732.
2015
Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.
Antimicrobial agents and chemotherapy.
59(9):5793-7
[DOI] 10.1128/AAC.00548-15.
[PMID] 26169413.
2015
Severity of influenza A(H1N1) illness and emergence of D225G variant, 2013-14 influenza season, Florida, USA.
Emerging infectious diseases.
21(4):664-7
[DOI] 10.3201/eid2104.141375.
[PMID] 25811540.
2014
Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.
Antimicrobial agents and chemotherapy.
58(8):4443-51
[DOI] 10.1128/AAC.00099-14.
[PMID] 24867988.
2014
Detection of Neisseria meningitidis from negative blood cultures and cerebrospinal fluid with the FilmArray blood culture identification panel.
Journal of clinical microbiology.
52(6):2262-4
[DOI] 10.1128/JCM.00352-14.
[PMID] 24740076.
2014
Enteric bacteria promote human and mouse norovirus infection of B cells.
Science (New York, N.Y.).
346(6210):755-9
[DOI] 10.1126/science.1257147.
[PMID] 25378626.
2014
High Percentage of False-Positive Results for Influenza B Obtained With a Rapid Influenza Point-Of-Care Test
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
59(4):605+-5
[DOI] 10.1093/cid/ciu315.
[PMID] 24795330.
2013
Log reduction of multidrug-resistant Gram-negative bacteria by the neutrophil-derived recombinant bactericidal/permeability-increasing protein.
International journal of antimicrobial agents.
42(6):571-4
[DOI] 10.1016/j.ijantimicag.2013.07.019.
[PMID] 24189329.
2013
Multi-functional analysis of Klebsiella pneumoniae fimbrial types in adherence and biofilm formation.
Virulence.
4(2):129-38
[DOI] 10.4161/viru.22974.
[PMID] 23302788.
2013
Resistance mechanisms in Campylobacter jejuni.
Virulence.
4(3):230-40
[DOI] 10.4161/viru.23753.
[PMID] 23406779.
2012
Antibacterial analysis of surgical adhesives.
Plastic and reconstructive surgery.
129(2):402e-404e
[DOI] 10.1097/PRS.0b013e31823af194.
[PMID] 22286489.
2011
Campylobacter capsule and lipooligosaccharide confer resistance to serum and cationic antimicrobials.
Virulence.
2(1):30-40
[PMID] 21266840.
2008
Reactive nitrogen species contribute to innate host defense against Campylobacter jejuni.
Infection and immunity.
76(3):986-93
[DOI] 10.1128/IAI.01063-07.
[PMID] 18174337.
2006
A paradigm for direct stress-induced mutation in prokaryotes.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
20(14):2476-85
[PMID] 17142797.
2004
Antibiotics in animal feed and spread of resistant Campylobacter from poultry to humans.
Emerging infectious diseases.
10(6):1158-9
[PMID] 15224671.
2004
Antimicrobial resistance in Campylobacter.
Emerging infectious diseases.
10(7)
[PMID] 15338553.
2002
The carboxyl-terminal domain of closely related endotoxin-binding proteins determines the target of protein-lipopolysaccharide complexes.
The Journal of biological chemistry.
277(10):7970-8
[PMID] 11773072.
1997
An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains.
Proceedings of the National Academy of Sciences of the United States of America.
94(20):10973-8
[PMID] 9380744.
1997
Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS.
The Journal of biological chemistry.
272(30):18682-5
[PMID] 9228038.
Grants
Sep 2022
ACTIVE
A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA LOS ANGELES
via NATL INST OF HLTH NIAID
Sep 2021
– Oct 2022
A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
Role: Principal Investigator
Funding: LEIDOS
via NATL INST OF HLTH NCI
May 2021
ACTIVE
Prevalence of Cefazolin Inoculum Effect in Mcthicillin Susceptible Staphylococcus aureus Bacteremia
Role: Co-Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Mar 2021
– Dec 2022
ACTIV 4d RAAS
Role: Principal Investigator
Funding: VANDERBILT UNIVERSITY MEDICAL CENTER
via NATL INST OF HLTH NHLBI
Oct 2020
ACTIVE
COVID-19: A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitals Adults with COVID-19
Role: Principal Investigator
Funding: NEW YORK UNIV
via NATL INST OF HLTH NHLBI
Mar 2020
– Aug 2021
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
Role: Principal Investigator
Funding: LEIDOS
via NATL INST OF HLTH NIAID
Sep 2016
– May 2018
Mucusal and Systemic Immunity, Vaccines and Microbiota Interplay in Humans
Role: Principal Investigator
Funding: UNIV OF MARYLAND COLLEGE PARK
via NATL INST OF HLTH NIAID
Education
Fellowship – Infectious Disease
2005
·
New York University
Residency – Internal Medicine
2002
·
New York University
Internship – Internal Medicine
2001
·
New York University
Medical Degree
2000
·
New York University
Doctor of Philosophy
1999
·
New York University
Bachelor of Arts – Biology
1992
·
City University of New York
Contact Details
Phones:
- Business:
- (352) 273-8606
Emails:
- Business:
- nicole.iovine@medicine.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100277
GAINESVILLE FL 32610